U.S. CDC Highlights High Unmet Cardiovascular Need
A new report published by the U.S. Centers for Disease Control and Prevention (CDC) sheds light on an issue that… more
Posted by Andrew JillionsPOSITIVELY PRECISE.
We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.
Learn More
Pipeline
Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.
learn moreRECENT PRESS RELEASES
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
- Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress
Latest Tweets
moreHEARTS & MINDS BLOG
Investor Day and July Meetings Recap
Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations. Prior to joining Esperion, I was… more
Posted by mlowe@esperion.comA Closer Look – June 2018
As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more
Posted by mlowe@esperion.com